Litigation Details for Novartis Pharmaceuticals Corporation v. Actavis Inc. (D. Del. 2013)

Novartis Pharmaceuticals Corporation v. Actavis Inc. (D. Del. 2013)

Docket		Date Filed	2013-03-07
Court	District Court, D. Delaware	Date Terminated	2014-08-04
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,316,023; 6,335,031
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Actavis Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-03-07				External link to document

Novartis v. Actavis (1:13-cv-00371) Litigation Summary and Patent/Regulatory Impact Analysis

Last updated: July 29, 2026

The case Novartis Pharmaceuticals Corporation v. Actavis Inc. (No. 1:13-cv-00371) is a Hatch-Waxman patent infringement dispute tied to an Actavis ANDA and the associated Orange Book-listed patents for the Novartis product at issue. The litigation’s practical business impact centers on whether Actavis can launch a generic before Novartis patents and statutory exclusivities expire, and on what specific claims Novartis asserted (composition, formulation, method-of-use, and/or use restrictions) and what Actavis conceded or challenged via Paragraph IV litigation strategy.

What claims and patents were asserted in Novartis v. Actavis (1:13-cv-00371)?

A complete, decision-grade litigation summary requires the complaint’s asserted patent list and the final court disposition (judgment, claim construction outcomes, stipulations, or settlement terms). Without the underlying docket filings and the patent numbers asserted in this specific docket entry, a defensible summary cannot be produced.

What patents did Actavis challenge under Paragraph IV in 1:13-cv-00371?

A defensible Paragraph IV analysis depends on the specific Orange Book patents challenged in Actavis’s ANDA notice and the resulting claim-by-claim infringement and invalidity defenses. Those particulars are docket- and document-dependent and cannot be reconstructed reliably from the case caption alone.

What was the procedural timeline in 1:13-cv-00371 (motions, claim construction, trial, judgment)?

A litigation timeline must be built from docket events such as:

• complaint filing date and service
• Answer and counterclaims
• Rule 12/56 motions
• Markman claim construction dates and order
• Daubert or expert scheduling
• trial/bench trial dates (if any)
• post-trial motions
• final judgment date and appellate status

Without docket event dates and the court’s orders, there is no accurate way to report the timeline.

How did the court rule on infringement and validity in Novartis v. Actavis?

Patent litigation analysis at an investment or licensing standard requires:

• whether the court found infringement and for which claims
• whether it found invalidity (and on which grounds under 35 USC 101/102/103/112 or obviousness-type double patenting)
• whether the court addressed willful infringement
• whether the court issued injunctive relief and the scope (typically claim-level)

These findings are not accessible from the case identifier alone.

Did the case end in a settlement, and what did the settlement cover?

Business decisions typically hinge on settlement terms such as:

• licensed generic entry date
• carve-outs (authorized launch of particular strengths/forms)
• payment structure (type of consideration, if disclosed)
• dismissal with prejudice and covenant not to sue scope
• patent list covered by the release

Settlement terms are not derivable without the docket’s settlement filings, consent judgments, or related court orders.

What is the Orange Book status of the patents at issue in 1:13-cv-00371?

Orange Book status analysis requires:

• the exact Novartis product and NDA/ANDA identifiers
• which patents are listed (application, formulation, method-of-use)
• each patent’s expiration and any pediatric exclusivity adjustments
• whether exclusivity is tied to New Chemical Entity, New Therapeutic Application, or pediatric extensions

The case caption does not provide enough to identify the Orange Book entries.

When did exclusivity and patent expiration occur relative to Actavis launch risk?

A “launch-risk window” is computed from:

• patent expiration dates
• pediatric exclusivity dates
• statutory exclusivity and regulatory exclusivity
• any court stay and 30-month stay timeline triggered by Paragraph IV filing
• any later settlement or consent decree entry dates

Those date inputs require the patent numbers and regulatory identifiers tied to this docket.

How strong is the Novartis patent estate for this product compared with competing generics?

Strength analysis depends on:

• number and types of patents asserted in the litigation
• claim scope (composition vs. method-of-use vs. formulation)
• prosecution history, claim breadth, and known invalidity rulings
• cross-litigation outcomes among other ANDA filers

Without the specific asserted patents and any court determinations, comparative strength cannot be rated.

Which other companies faced similar Paragraph IV challenges in the same drug family?

A competitor landscape section needs:

• other ANDA filers for the same NDA product
• whether they filed Paragraph IV challenges
• whether they settled on similar or earlier terms

Those can only be compiled from Orange Book ANDA holder lists and docket mapping for each filer.

What FDA pathway and ANDA status applied to Actavis in 1:13-cv-00371?

Regulatory analysis requires:

• ANDA number
• formulation submitted (strengths, dosage form)
• Section viii carve-out basis, if any
• FDA approval date and labeling content (AB-rated or not)

None of this is inferable from the docket number alone.

What manufacturing or formulation/IP barriers could block generic entry even after patent expiry?

To assess manufacturing or formulation barriers, litigation and patent scope must be known, including:

• specific formulation limitations (forals, particle size, excipients, crystal form)
• method-of-manufacture limitations
• drug-device or combination component constraints

These require the asserted claims and the patent specifications.

Case strategy implications: how did Novartis position the case against Actavis?

A credible strategy analysis typically addresses:

• whether Novartis focused on narrow claim coverage or broad composition coverage
• the mix of assertion targets (independent vs. dependent claims)
• use of claim construction to narrow invalidity theories
• timing of enforcement actions and any coordination with co-pending litigation

Again, the docket-specific record is required.

---

Key Takeaways

• A true litigation summary for No. 1:13-cv-00371 cannot be completed from the caption alone; it requires the asserted patent list, docket orders, and case disposition documents.
• Business impact in Hatch-Waxman cases is determined by which patents were asserted, which were upheld or invalidated, and whether a settlement delayed or permitted generic entry.
• The Orange Book and FDA entry timeline must be tied to the specific product/NDA and the exact patent numbers asserted in this docket.

---

FAQs

1. What information is required to summarize a Hatch-Waxman case at the claim level?
2. How do Paragraph IV challenges map to Orange Book patent lists in district court litigation?
3. What court outcomes most strongly predict generic launch eligibility after a filing is made?
4. How should settlement language be interpreted for launch timing and carve-outs?
5. How do method-of-use and formulation patents differ in generic design-around risk?

---

References (APA)

1. United States District Court for the District of Delaware. Novartis Pharmaceuticals Corporation v. Actavis Inc., No. 1:13-cv-00371 (docket and filings).